Home›Stock Screener›Beryl Drugs

Beryl Drugs Share Price Today | Stock Price & Beryl Drugs Share Screener

BERLDRG Pharmaceuticals & Biotechnology
Live Share Price BSE
₹25.84
▲ 0.12 (0.47%)
2026-11-18 00:00:00

As of November 18, 2026, the live Beryl Drugs share price (BSE: BERLDRG) is ₹25.84, up 0.47% from the previous close, with shares trading between ₹25.00 and ₹26.00 in today's trading session, and a 52-week range of ₹16.87–₹26.31. Track Beryl Drugs market cap to gauge the company's total market size. Use the Beryl Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Beryl Drugs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹24 and net income of ₹1, with EBITDA of ₹2, an operating margin of 5.0% and a profit margin of 4.2%.

Beryl Drugs Market Cap ₹12.71 Cr.
BERLDRG P/E Ratio (TTM) 19.50
Beryl Drugs P/B Ratio 1.23
EPS (TTM) ₹0.84
Dividend Yield -
Debt to Equity 0.34
BERLDRG 52 Week High ₹26.31
Beryl Drugs 52 Week Low ₹16.87
Operating Margin 5.00%
Profit Margin 4.17%
BERLDRG Revenue (TTM) ₹24.00
EBITDA ₹2.00
Net Income ₹1.00
Total Assets ₹15.00
Total Equity ₹10.00

Beryl Drugs Share Price Chart

Track the current stock price of Beryl Drugs with an interactive chart. Analyse BERLDRG share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Beryl Drugs stock quote in one place.

The quote of ₹25.84 sits between the 52-week low of ₹16.87 and the 52-week high of ₹26.31, and the latest session moved 0.47% from the previous close.

Beryl Drugs Company Profile - Fundamental Screener

Screen Beryl Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BERLDRG shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE415H01017.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE415H01017

Beryl Drugs Balance Sheet Screener

Screen BERLDRG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹15, down from ₹16 in 2025.

Latest statistics put total assets at ₹15 and shareholder funds at ₹10, with a leverage ratio of 0.34.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 15 16 18 18 18 19 17 15 11 10
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 7 6 6 6 6 8 9 2 2 2

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 1 2 3 3 2 3 3 2 0 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 10 10 9 8 7 8 8 8 7 6
Share Capital 5 5 5 5 5 5 5 5 5 5
Reserves & Surplus 5 4 4 3 2 3 3 2 2 1

Beryl Drugs Income Statement Screener - Profit & Revenue Analysis

Screen Beryl Drugs income statement and profit fundamentals. Analyze BERLDRG quarterly results. Beryl Drugs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹24 and net profit was ₹1, equal to earnings per unit of ₹1.30, at an operating margin of 5%.

In that period expenses were ₹22, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹19 and net profit of ₹0.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 24 19 23 27 27 15 14 13 13 16 11 14 14
Expenses 22 17 20 25 25 14 13 12 12 14 11 13 13

Operating Costs and Margins

EBITDA 2 2 3 3 2 1 2 1 1 2 0 1 1
Operating Profit % 5.00% 10.00% 6.00% 9.00% 7.00% 3.00% 10.00% 7.00% 8.00% 7.00% -1.00% 4.00% 6.00%
Depreciation 1 2 1 1 1 1 1 1 0 0 0 0 1
Interest 0 0 1 1 0 0 1 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 1 1 1 1 1 -1 0 0 1 1 0 0 0
Tax 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 1 0 1 1 1 -1 0 0 1 1 0 0 0
EPS 1.30 0.84 1.14 1.52 1.51 -1.30 0.47 0.09 1.16 1.96 -0.88 0.33 0.17

Beryl Drugs Cash Flow Screener - Liquidity Fundamentals

Screen BERLDRG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹4, and net cash flow was an outflow of ₹1.

Over the same period, investing activities used ₹2 and financing activities used ₹2.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 4 3 1 3 0 0 0 3 0 0
Investing Activities -2 -1 -1 -1 1 0 -2 -5 0 0

Financing and Net Cash

Financing Activities -2 -2 0 -1 0 -1 2 2 0 0
Net Cash Flow -1 1 0 0 0 0 0 0 -1 1

Beryl Drugs Shareholding Pattern Screener

See Beryl Drugs shareholding pattern with promoter, FII, and DII holdings. Check Beryl Drugs promoter holding and ownership changes for BERLDRG on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 27.48%, foreign institutions 0.00%, domestic institutions 0.00% and the public 64.94%, spread across 7,349 shareholders.

The shareholder count was 7,349 in 2026-Mar, compared with 7,309 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 27.48% 27.82% 27.97% 26.38% 26.38% 26.38% 26.38% 26.38%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 64.94% 63.56% 63.47% 68.53% 68.69% 68.71% 66.25% 66.26%
Other Holding 7.59% 8.62% 8.56% 5.08% 4.93% 4.91% 7.37% 7.35%
Shareholder Count 7,349 7,309 7,296 7,431 7,415 7,446 7,409 7,257

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Beryl Drugs. Beryl Drugs dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Beryl Drugs.

Beryl Drugs Stock Index Membership - Nifty & Sensex

See which indices include Beryl Drugs stock. Check BERLDRG index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Beryl Drugs is not part of any tracked indices.
Only major market indices are tracked in our system.

Beryl Drugs Market Events Screener - Corporate Actions

Get Beryl Drugs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Beryl Drugs stock events that may affect BERLDRG share price, along with derivatives, futures and options activity and sector gainers.

14 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 14, 2026, with a record date of November 14, 2026.

It is followed by Annual General Meeting dated September 29, 2026 and Quarterly Result Announcement dated August 11, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-14 2026-11-14 Quarterly Result Announcement NA -2.96%
2026-09-29 2026-09-29 Annual General Meeting NA -2.13%
2026-08-11 2026-08-11 Quarterly Result Announcement NA 8.77%
2026-05-28 2026-05-28 Quarterly Result Announcement NA -1.24%
2026-05-11 2026-05-11 Extraordinary General Meeting NA 6.79%
2026-03-16 2026-03-16 Extraordinary General Meeting NA -6.91%
2026-02-09 2026-02-09 Quarterly Result Announcement NA -1.32%
2025-11-13 2025-11-13 Quarterly Result Announcement NA 1.70%
2025-09-30 2025-09-30 Annual General Meeting NA -16.04%
2025-08-07 2025-08-07 Quarterly Result Announcement NA -3.22%
2025-05-30 2025-05-30 Quarterly Result Announcement NA -4.64%
2025-02-08 2025-02-08 Quarterly Result Announcement NA -6.59%
2024-11-13 2024-11-13 Quarterly Result Announcement NA 0.30%
2024-09-30 2024-09-30 Annual General Meeting NA -1.84%

Beryl Drugs Competitors Screener - Peer Stocks Comparison

Screen BERLDRG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

Beryl Drugs Company Announcements - News & Reports Screener

Screen BERLDRG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 18, 2026.

The next most recent announcements are dated November 18, 2026 and November 10, 2026.

Date Update Actions
2026-11-18 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2026 -
2026-11-18 Board Meeting Outcome for OUTCOME OF BOARD MEETING -
2026-11-10 Board Meeting Intimation for To Consider And Approve Unaudited Financial Results For The Quarter Ended 30Th September 2026 -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-07 Compliance-57 (5) : intimation after the end of quarter -
2026-09-30 Closure of Trading Window -
2026-09-30 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-29 PROCEEDINGS OF 33RD ANNUAL GENERAL MEETING HELD ON 29TH SEPTEMBER 2026 -
2026-09-29 Approval For Increase In The Limit Of Material Related Party Transactions With M/S. Aminova Infusions Pvt. Ltd. -
2026-09-29 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-06 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-03 Reg. 34 (1) Annual Report. -
2026-09-03 33RD ANNUAL GENERAL MEETING NOTICE TO BE HELD ON 29TH SEPTEMBER 2026 AT 11 A.M. AT KANCHAN PALACE COMMUNITY HAII NIPANIA RING ROAD INDORE -
2026-09-03 EVOTING DATE FOR THE PURPOSE OF 33RD ANNUAL GENERAL MEETING -
2026-09-03 RECORD DATE FOR THE PURPOSE OF 33RD ANNUAL GENERAL MEETING -
2026-09-02 ANNUAL BOOK CLOSURE -
2026-09-02 Board Meeting Outcome for OUTCOME OF BOARD MEETING -
2026-08-27 Board Meeting Intimation for Approve Board Report And Other Matters Related To 33Rd Annual General Meeting Of The Company -
2026-08-20 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 -
2026-08-19 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹25.84, within a 52-week range of ₹16.87 to ₹26.31. The P/E ratio is 19.50 and the P/B ratio is 1.23, with earnings per unit of ₹0.84. Market capitalisation stands at ₹12.71 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.